Swedish medical imaging and cybersecurity company Sectra has signed an agreement to acquire Lithuanian radiology AI startup Oxipit, with the transaction expected to close in March 2026. The acquisition reflects a broader shift in medical imaging technology, particularly the growing role of artificial intelligence in addressing rising imaging volumes and a global shortage of radiologists.
Most radiology AI systems currently operate as decision-support tools, acting as a “co-pilot” that flags potential findings for clinicians to review. Oxipit, however, has focused on developing autonomous AI capable of independently performing certain diagnostic tasks without human input. Its flagship product, ChestLink, has received CE Class IIb certification—the first autonomous AI system in the world approved at this level for analysing chest X-rays.
ChestLink is designed to automatically detect and clear high-confidence “normal” chest X-rays from a radiologist’s worklist. This capability addresses a major operational challenge in imaging departments: a large share of daily scans, particularly routine chest X-rays, show no abnormalities. By automatically finalising reports for clearly normal images under strict safety thresholds, the system allows radiologists to focus their time on more complex cases that require clinical judgement.
Following the acquisition, the Oxipit team will become a dedicated AI development centre within Sectra’s Imaging IT Solutions division. At the same time, Sectra’s Amplifier service will continue operating as an open, vendor-neutral platform that enables healthcare organisations to integrate third-party AI applications.
Beyond the technology itself, regulatory approval represents a key barrier in healthcare AI. Autonomous diagnostic systems face far stricter oversight than conventional computer-aided detection tools. ChestLink’s CE Class IIb certification demonstrates that the technology meets high standards for clinical validation and safety within the European Economic Area. By acquiring Oxipit, Sectra gains not only the underlying AI technology but also a team with proven experience navigating complex regulatory requirements for autonomous medical systems.
Click here to read the original news story.